A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator’s Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator’s Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
Patologie
Stato
Attivo - reclutamento chiuso
Codice studio
C-800-25
Codice EudraCT
2022-502065-23
Sponsor/Promotore
Agenus, Inc.
Tipologia
Sperimentale
Fase
II
Unità Operativa
UOS Sperimentazioni cliniche fasi precoci
Principal Investigator